Atezolizumab/bevacizumab and lenvatinib for hepatocellular carcinoma: A com-parative analysis in a European real-world cohort.

de Castro T, Welland S, Jochheim L, Leyh C, Shmanko K, Finkelmeier F, Jeliazkova P, Jefremow A, Gonzalez-Carmona MA, Kandulski A, Roessler D, Ben Khaled N, Enssle S, Venerito M, Fründt TW, Schultheiß M, Djanani A, Pangerl M, Maieron A, Wirth TC, Marquardt JU, Greil R, Fricke C, Günther R, Schmiderer A, Bettinger D, Wege H, Scheiner B, Müller M, Strassburg CP, Siebler J, Ehmer U, Waidmann O, Weinmann A, Pinter M, Lange CM, Saborowski A, Vogel A.

Hepatol Commun. 2024 Nov 4;8(11):e0562. doi: 10.1097/HC9.0000000000000562. eCollection 2024 Nov 1. PMID: 39495153.

https://pubmed.ncbi.nlm.nih.gov/39495153/